Serpin Pharma, LLC
USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Serpin ranks #37,419 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.
- #37,419
- of 49,997 US assignees by volume
- 11th percentile
- by Innovation Score (22.8/100)
- 12.1
- avg claims per patent
- +0%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R37419 · US Corporation #37,419 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL
- GRANTS-MICRO 7 grants
- MID-PACK #37,419/49,997
- PHOTO-FINISH Seppi M SPA
- CPC-NARROW A61P · 3 areas
- INNOV-THIN 22.8/100
- CLAIMS-RICH 12.1 claims/avg
- TYPE-USCORP US Corporation
- VEL-FLAT +0% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Seppi M. SPA AG (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Serpin’s 22.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Serpin
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Serpin Pharma · this assignee 23
Serpin Pharma · this assignee
23 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Serpin's Innovation Score is 22.8/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Serpin?
Each dot is one of Serpin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Serpin’s own 12.1 claims/patent is at or below the 12.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Serpin's grants concentrate
Serpin Pharma, LLC is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2015. By volume, Serpin sits between Seppi M. SPA AG and Sexy Back BRA, LLC.
Serpin's three-year grant acceleration
Serpin Pharma, LLC shows 1 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Serpin's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Seppi M SPA
Seppi M. SPA AG
7 patents
- Septeos
Septeos
7 patents
- Sera4
Sera4 Ltd.
7 patents
- Serb
Serb SA
7 patents
- SET North America
SET North America, LLC
7 patents
- Seti-tec
Seti-tec
7 patents
- Seventy Eight
Seventy Eight Co., Ltd.
7 patents
- Sexy Back BRA
Sexy Back BRA, LLC
7 patents
- Serpin Pharma ◀
Serpin Pharma, LLC
7 patents
What this shows Serpin holds 7 patents at rank #37,353, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Serpin
By rank, the assignees closest to #37,353 in granted patent volume.
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Serpin's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Serpin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
23 11th percentile higher than 11% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 14.3% |
| 2018 | 1 | 14.3% |
| 2019 | 1 | 14.3% |
| 2021 | 2 | 28.6% |
| 2023 | 1 | 14.3% |
| 2025partial year | 1 | 14.3% |
Which technologies does Serpin Pharma, LLC patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Serpin Pharma, LLC's patent record in context - here's where to go next.
- Serpin Pharma, LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #37,419 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Serpin Pharma, LLC against Seppi M. SPA AG, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 22.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.